Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9252276 | 0.88 | CYP1A2 (0.44) | CYP1A2 | |
| SCHEMBL11927964 | 0.87 | MEN1 (0.35) | CYP2C9CYP2C19 | |
| SCHEMBL10125737 | 0.82 | — | — | |
| SCHEMBL29955693 | 0.78 | CYP1A2 (0.41) | CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6913970 | 0.78 | EPHX1 (0.31) | — | |
| SCHEMBL6913975 | 0.72 | SMYD3 (0.32) | — | |
| SCHEMBL20124735 | 0.72 | — | — | |
| SCHEMBL888643 | 0.71 | — | — | |
| SCHEMBL18212652 | 0.71 | LMNA (0.38) | CYP1A2CYP2C19 | |
| SCHEMBL6913788 | 0.71 | MMP1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688711-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160368942-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Cipla USA, Inc. | 2016-12-22 | — | — | US | disclosed |
| US-9266919-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150045317-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Cipla USA, Inc. | 2015-02-12 | — | — | US | disclosed |
| US-8658606-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8653042-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8524675-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524689-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8399419-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8372813-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120283207-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120283208-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120208781-A1 | AMINOGLYCOSIDE DOSING REGIMENS | ACHAOGEN, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120172332-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120165282-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120135948-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135945-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135946-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20110275586-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135948-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QARS1 | CYP1A2 1336/4885CYP2C9 1140/4885CYP2C19 1307/4885 |
| US-20120283208-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QTRT1 | CYP1A2 1081/4885CYP2C9 1553/4885CYP2C19 1475/4885 |
| US-20120135946-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QARS1 | CYP1A2 1551/4885CYP2C9 1147/4885CYP2C19 1404/4885 |
| US-20160368942-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | CYP1A2 2298/4885CYP2C9 260/4885CYP2C19 731/4885 |
| US-20110275586-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, MRPS23 | CYP1A2 1195/4885CYP2C9 1287/4885CYP2C19 1176/4885 |
| US-20150045317-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | CYP1A2 2298/4885CYP2C9 260/4885CYP2C19 731/4885 |
| US-20120172332-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QARS1 | CYP1A2 1267/4885CYP2C9 1166/4885CYP2C19 1228/4885 |
| US-20120135945-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QARS1 | CYP1A2 1496/4885CYP2C9 1109/4885CYP2C19 1339/4885 |
| US-20120283207-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QTRT1 | CYP1A2 1081/4885CYP2C9 1553/4885CYP2C19 1475/4885 |
| US-20120165282-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, QARS1, NQO2 | CYP1A2 1530/4885CYP2C9 1324/4885CYP2C19 1467/4885 |
| US-20120208781-A1 | AMINOGLYCOSIDE DOSING REGIMENS | ATP6V1B1, GLS, NRDC | CYP1A2 2047/4885CYP2C9 2068/4885CYP2C19 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.